Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Reexamination Certificate
2007-06-05
2007-06-05
Saeed, Kamal A. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
C562S500000, C564S384000
Reexamination Certificate
active
11014460
ABSTRACT:
Compounds of formulas 1 through 17 provided in the specification specifically or selectively inhibit either the cytochrome P450RAI-1 enzyme or the cytochrome P450RAI-2 enzyme.
REFERENCES:
patent: 4326055 (1982-04-01), Loeliger
patent: 5349105 (1994-09-01), Chandraratna
patent: 5648503 (1997-07-01), Vuligonda et al.
patent: 5723666 (1998-03-01), Vuligonda et al.
patent: 5952345 (1999-09-01), Klein et al.
patent: 6252090 (2001-06-01), Vasudevan et al.
patent: 6291677 (2001-09-01), Vasudevan et al.
patent: 6303785 (2001-10-01), Vasudevan et al.
patent: 6313107 (2001-11-01), Vasudevan et al.
patent: 6369225 (2002-04-01), Vasudevan et al.
patent: 6369261 (2002-04-01), Johnson et al.
patent: 6380256 (2002-04-01), Vasudevan et al.
patent: 2002/0160986 (2002-10-01), Vasudevan et al.
patent: 2002/0183285 (2002-12-01), Vasudevan et al.
patent: 1 277 227 (1972-06-01), None
patent: WO 200218361 (2002-03-01), None
Sengupta S et al: “Indoarenediazonium salts: a new class of aromatic substrates for differential palladium catalyzed reations” Tetrahedron Letters, vol. 39, No. 7, Feb. 12, 1998, pp. 715-718, XP004106780 the whole document, particularly compound 8.
Castro C E et al: “Copper(I) substitutions. Scope and mechanism of cuprous acetylide substitutions” Journal of the American Chemical Society, vol. 91, No. 23, Nov. 5, 1969, pp. 6464-6470, XP002326252 the whole document, particularly table VI, 5thentry.
Asao N et al: “Pi-pi chelation controlled chemoselective conjugate addition of lithium dimethylcuprate” Tetrahedron Letters, vol. 44, No. 9, Feb. 24, 2002, pp. 1803-1805, XP004408806 the whole document, particularly compounds 1a and 2a.
Costa A et al: “P2-Et-mediated deprotonation of ortho-halobenzyl sulfones: synthetic applications as zwitterionic synthons” SYNLETT, vol. 12, 2001, pp. 1881-1884, XP001084388 the whole document, particularly compound 13.
Hamon D P G et al: “Enantioselective syntheses of 2-arylpropanoic acid non-steroidal anti-inflammatory drugs and related compounds” TETRAHEDRON, vol. 51, No. 46, Nov. 13, 1995, pp. 12645-12660, XP004104649 the whole document, particularly compounds 35a and 35b.
Bouchain G et al: “Development of potential antitumor agents. Synthesis and biological evaluation of a new set of sulfonamide derivatives as histone deacetylase inhibitors” Journal of Medicinal Chemistry, vol. 46, No. 5, Feb. 27, 2003, pp. 820-830, XP002292252 the whole document, particularly pp. 827 and 828, compounds 20 and 21.
Xin Z et al: “A practical and efficient intramolecular Michael addition of ureas to alpha, beta-unsaturated esters” Tetrahedron Letters, vol. 41, No. 8, Feb. 2000, pp. 1147-1150, XP004188577 the whole document, particularly compounds 2a, 2b, 2e, 2f and 2g.
Nakao K et al: “Qualitative structure-activity analyses of novel hydroxyphenylurea derivatives as antioxidants” Bioorganic & Medicinal Chemistry, vo. 6, No. 6, 1998, pp. 849-868, XP002309788 the whole document, particularly compound 22.
Kwon B-M et al: “Synthesis and biological activity of cinnamaldehydes as angiogenesis inhibitors” Bioorganic & Medicinal Chemistry Letters, vol. 7, No. 19, Oct. 7, 1997, pp. 2473-2476, XP004136467 the whole document, particularly compound 2k.
Konek F Von et al: “Uber einige neue Derivate de Paracumar- und Vanillinsaure” Chemische Berichte, vol. 51, 1918, pp. 855-865, XP002326243 the whole document, particularly paragraph bridging pp. 857 and 858.
White et al. Identification of the human cytochrome P450, P450RAI-2, which is predominantly expressed in the adult cerebellum and is responsible for alltransretinoic acid metabolism, Prac. Natl. Acad. Sci. USA vol. 97 No. 12 pp. 6403-6408 (2000).
Kuijpers, et al., “The effects of oral liarozole on epidermal proliferation and differentiation in severe plaque psoriasis are comparable with those of acitretin,”British Journal of Dermatology, (1998) 139: pp. 380-389.
Kang, et al., “Liarozole Inhibits Human Epidermal Retinoid Acid 4-Hydroxylase Activity and Differentially Augments Human Skin Responses to Retinoic Acid and Retinol In Vivo,”The Journal of Investigative Dermatology, (Aug. 1996) vol. 107, No. 2: pp. 183-187.
Van Wauwe, et al., “Liarzole, an Inhibitor of Retinoic Acid Metabolism, Exerts Retinoid-Mimetic Effects in Vivo,”The Journal of Pharmacology and Experimental Therapeutics, (1992) vol. 261, No. 2: pp. 773-779.
De Porre, et al., “Second Generation Retinoic Acid Metabolism Blocking Agent (Ramba) R116010: Dose Finding in Healthy Male Volunteers,” University of Leuven, Belgium, p. 30.
Wauwe, et al., “Ketoconazole Inhibits the in Vitro and in Vivo Metabolism of All-Trans-Retinoic Acid,”The Journal of Pharmacology and Experimental Therapeutics, (1998) vol. 245, No. 2: pp. 718-722.
White, et al., cDNA Cloning of Human Retinoic Acid-metabolizing Enzyme (hP450RAI) Identifies a Novel Family of Cytochromes P450,The Journal of Biological Chemistry, (1997) vol. 272, No. 30, Issue of Jul. 25 pp. 18538-18541.
Hanzlik, et al., “Cyclopropylamines as Suicide Substrates for Cytochromes P450RAI,”Journal of Medicinal Chemistry, (1997), vol. 22, No. 7, pp. 759-761.
Ortiz de Montellano, “Topics in Biology—The Inactivation of Cytochrome P450RAI,”Annual Reports in Medicinal Chemistry, (1984), Chapter 20, pp. 201-210.
Hanzlik, et al. “Suicidal Inactivation of Cytochrome P450RAI by Cyclopropylamines-Evidence for Cation-Radical Intermediates,”J. Am. Chem. Soc., (1982), vol. 104, No. 107, pp. 2048-2052.
Bligh et al. (1959) Canadian Journal of Biochemistry 37, 911-917.
Lopez, et al. in Tet Lett., 1999, 40, 11, p. 2071-2074.
Barlaam et al. J. Med. Chem., 1999, 42, 23, 4890-4908.
Floyd et al., Journal of Pharmaceutical Sciences, 1970, 59 (6), p. 869-870.
Teng, et al, Journal of Medicinal Chemistry, 1996, 39, p. 3035-3038.
Beard Richard
Bhat Smita
Chandraratna Roshantha A.
Li Ling
Liu Xiaoxia
Allergan Inc.
Grazier Nyeemah
Hamilton Brook Smith & Reynolds P.C.
Saeed Kamal A.
LandOfFree
Compounds having selective cytochrome P450RAI-1 or selective... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds having selective cytochrome P450RAI-1 or selective..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds having selective cytochrome P450RAI-1 or selective... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3832010